ANDA 75536, held by Teva. Doxazosin Mesylate.
As of Nov 16, 2026, ANDA 75536 (Doxazosin Mesylate), held by Teva, was first approved by FDA on Oct 18, 2000, with 10 approved supplements and 0 published complete response letters.
Doxazosin tablets are an alpha 1 adrenergic antagonist indicated for: Signs and symptoms of Benign Prostatic Hyperplasia (BPH) Treatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 18, 2000 | Original application | Approved |
| Doxazosin MesylateEQ 1MG BASE · tablet;oral | Doxazosin Mesylate | Rx |
| Doxazosin MesylateEQ 2MG BASE · tablet;oral | Doxazosin Mesylate | Rx |
| Doxazosin MesylateEQ 4MG BASE · tablet;oral | Doxazosin Mesylate | Rx |
| Doxazosin MesylateEQ 8MG BASE · tablet;oral | Doxazosin Mesylate | Rx |
| Sep 29, 2017 | Supplement 18Labeling · Standard review | Approved | None posted |
| Feb 21, 2017 | Supplement 19Labeling · Standard review | Approved | None posted |
| Apr 26, 2013 | Supplement 10Labeling | Approved | None posted |
| Jun 15, 2010 | Supplement 9Labeling | Approved | None posted |
| Dec 15, 2006 | Supplement 7Labeling | Approved | None posted |
| Mar 26, 2004 | Supplement 6Labeling | Approved | None posted |
| Jul 14, 2003 | Supplement 5Labeling | Approved | None posted |
| Jun 17, 2002 | Supplement 3Manufacturing | Approved | None posted |
| Dec 26, 2001 | Supplement 2Manufacturing | Approved | None posted |
| Apr 25, 2001 | Supplement 1Labeling | Approved | None posted |
| Oct 18, 2000 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters